PTPI vs PRGO vs HIMS vs TDOC vs OPRX

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). OptimizeRx Corporation (OPRX) offers the better valuation at 23. 9x trailing P/E (6. 8x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 23.

9x versus Hims & Hers Health, Inc. at 55. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.

21β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 104% more volatile than PRGO relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — PTPI leads at 76. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 52. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PTPI (100.

0% yield), PRGO (9. 8% yield) pay a dividend. HIMS, TDOC, OPRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

21), 9. 8% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, TDOC: -38. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTPI is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. PTPI, PRGO pay a dividend while HIMS, TDOC, OPRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.